BioPharmSignal logoBioPharmSignal

Biotech News

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

Aquestive Therapeutics (AQST)Aquestive TherapeuticsCompany update

Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company

Related news

AQSTAquestive Therapeutics2026-03-30 11:00 EST

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

AQSTAquestive Therapeutics2026-08-10 11:00 EST

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

View all latest news

Aquestive Therapeutics

Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without...

Recent company news

AQSTAquestive Therapeutics2026-08-11 20:01 EST

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-08-10 11:00 EST

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

AQSTAquestive Therapeutics2026-07-29 11:00 EST

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-07-07 11:00 EST

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

AQSTAquestive Therapeutics2026-05-13 20:01 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
4.29 USD
Market cap
493.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States